Physician profile
Molly B Gray
NPI 1760641187
$1,378.19
in general payments reported to CMS, 2019-2025
23 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.57 · 2020: $67.63 · 2021: $308 · 2022: $244 · 2023: $258 · 2024: $295 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.21 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $187.77 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $102.75 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Gm Pharmaceuticals, INC. | $89.55 | 2022 | |
| Lilly USA, LLC | $88.77 | 2020-2024 | Mounjaro |
| Abbvie INC. | $74.30 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $65.35 | 2021 | |
| Pfizer INC. | $52.19 | 2020-2023 | |
| Medtronic, INC. | $43.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.65 | 2021 | |
| Eisai INC. | $37.74 | 2021 | |
| Axsome Therapeutics, INC. | $34.43 | 2025 | Auvelity |
| Biogen, INC. | $34.37 | 2025 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $31.11 | 2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $30.75 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.22 | 2021 | |
| Horizon Therapeutics Plc | $22.57 | 2019 | |
| Exact Sciences Corporation | $21.28 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $17.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.47 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2023 | |
| Organon LLC | $12.89 | 2022 | |
| Ucb, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.